Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

3(30%)

Results Posted

75%(3 trials)

Terminated

2(20%)

Phase Distribution

Ph not_applicable

10%

Ph phase_1

40%

Ph phase_2

40%

Ph phase_3

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

4(40.0%)

Phase 2Efficacy & side effects

4(40.0%)

Phase 3Large-scale testing

1(10.0%)

N/ANon-phased studies

1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Terminated(2)

Other(1)

Detailed Status

Completed4

Terminated2

Recruiting2

Active, not recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (40.0%)

Phase 24 (40.0%)

Phase 31 (10.0%)

N/A1 (10.0%)

Trials by Status

terminated220%

completed440%

active_not_recruiting110%

recruiting220%

unknown110%

Recent Activity

3 active trials

Showing 5 of 10

recruitingphase_2

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

NCT04895761

recruitingphase_3

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

NCT04314219

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07616154Phase 2

Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease

Recruiting

NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated

NCT03349450Phase 2

DPX-Survivac and Checkpoint Inhibitor in DLBCL

Completed

NCT04895761Phase 1

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active Not Recruiting

NCT04314219Phase 3

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

Recruiting

NCT02583828Not Applicable

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

Completed

NCT05243524Phase 2

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Terminated

NCT04262427Phase 1

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Unknown

NCT00326417Phase 1

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

Completed

NCT03139851Phase 2

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

Completed

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10